

Annex II

Number of patients prescribed with conventional and new generation antipsychotic drugs and the medication expenditure involved in the HA from 2019-20 to 2023-24 (up to 31 December 2023)

	Conventional antipsychotic drugs			New generation antipsychotic drugs		
	Number of patients prescribed with oral drugs	Number of patients prescribed with long-acting injectable antipsychotics	Medication expenditure involved (\$ million)	Number of patients prescribed with oral drugs	Number of patients prescribed with long-acting injectable antipsychotics	Medication expenditure involved (\$ million)
2019-20	35 200	9 900	42	94 400	3 700	280
2020-21	32 500	9 400	41	99 400	4 100	313
2021-22	30 300	9 000	35	104 300	4 400	344
2022-23	28 300	8 500	42	107 300	4 600	365
2023-24 (Projection as of 31 December 2023)	27 200	8 300	32	111 300	5 000	392

Note 1:

Figures are rounded to the nearest hundred.

Note 2:

Depending on the patients' clinical conditions and needs, the drugs prescribed may vary from time to time and some patients may be prescribed both oral and injectable psychiatric drugs concurrently.